Board Changes

29 May 2020

READING, UNITED KINGDOM (29 May 2020) – Dr Ros Rivaz has advised the Board of ConvaTec Group Plc ("ConvaTec" or "the Company") that she wishes to resign as a Non-Executive Director of the Company with effect from 31 August 2020 whereupon she shall take up the role of Chair of the Nuclear Decommissioning Agency.

Dr John McAdam, Chairman, said “On behalf of the Board I would like to thank Ros for her significant contribution to ConvaTec since she became a Director in 2017, and for serving as Chair of the Remuneration Committee since March 2019. We wish her well with her new role as Chair of the Nuclear Decommissioning Agency.”

This announcement is made in accordance with Listing Rule 9.6.11R(1).



Analysts and Investors

Mark Reynolds, Director Investor Relations    

+44 (0)7551 036 625



Buchanan: Charles Ryland / Chris Lane / Vicky Hayns      

+44 (0)207 466 5000

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92


About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has established market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.

Cookies are needed for this website to work optimally. They also help us to know a little bit about how you use our website, which improves the browsing experience.  Cookies on this site are used for traffic measurement and optimisation of page content only. By continuing to browse on this website, you indicate your consent to the use of cookies.  You may block the use of cookies by following the "How to block and avoid cookies" instructions

Learn more about our Cookie policy